艾昆纬-驯服复杂的临床试验生态系统-一种已经产生影响的新方法（英）-2025_8页_2mb

One Home for Sites: Simplifying the Complex Clinical Trial Ecosystem

Introduction to the Problem

The clinical trial ecosystem has expanded with numerous technology solutions, leading to administrative overload for trial sites due to multiple portals and interfaces. This complexity causes inefficiency, burnout, and high turnover among site staff, with an average of 12-15 vendors per study, amplifying the issue across simultaneous studies.

What is One Home?

One Home is a vendor- and sponsor-agnostic, single sign-on (SSO) solution developed by IQVIA Technologies. It provides a streamlined way for sites to access multiple clinical systems without duplication, enabling efficient study organization and reducing tech-related burden.

Key Features

• Supports SSO across over 25 integrated systems in the free site version.
• Offers automated setup for studies and systems in the licensed version.
• Includes a customizable dashboard for tailored user experiences.
• Facilitates collaboration by allowing users to invite teams and manage tasks.
• Provides feedback mechanisms for continuous improvement based on industry input.

Benefits and Adoption

• Reduces user effort and improves efficiency, with adoption in 50+ countries by sites and technology providers.
• The free site version allows self-registration for immediate SSO access, while the licensed version simplifies setup for sponsors and CROs.
• Industry feedback drives agile development, with features like automated tasks and content management under review to further enhance usability.

Industry Feedback

Users report significant reductions in daily tasks, fewer logins, and better experience with seamless access across platforms, fostering collaboration and alignment across sponsors, sites, and tech vendors. Feedback directly informs product enhancements.

Future Directions

IQVIA Technologies uses agile methods to evaluate and release new features, focusing on automating tasks and managing system integrations to support evolving clinical trial needs.